SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
PURE Bioscience, Inc. (PURE) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 34/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✗
HEALTH
25/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — PURE
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.02
Book Value / Share$0.00
Revenue / Share$19.68
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-0.38 |
$1.29M |
$-21.69M |
-1682.3% |
| 2017 |
$-0.10 |
$1.83M |
$-6.52M |
-356% |
| 2018 |
$-0.11 |
$1.77M |
$-7.48M |
-421.4% |
| 2019 |
$-0.09 |
$1.91M |
$-6.56M |
-343.7% |
| 2020 |
$0.00 |
$6.92M |
$-6K |
-0.1% |
| 2021 |
$-0.03 |
$3.93M |
$-2.32M |
-59.1% |
| 2022 |
$-0.04 |
$1.85M |
$-3.5M |
-188.7% |
| 2023 |
$-0.04 |
$1.88M |
$-3.96M |
-211% |
| 2024 |
$-0.03 |
$1.96M |
$-3.35M |
-170.7% |
| 2025 |
$-0.02 |
$2.2B |
$-2.4M |
-0.1% |
